Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhaoming Li

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Oncotarget|July 8, 2016
Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149Lei Zhang, Sisi Jia, Yangyang Ma, et al.
Immunotherapy|June 26, 2020
A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphomaXinfeng Chen, Xin Li, Yanfen Liu, et al.
Therapeutic Advances in Medical Oncology|March 9, 2026
Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysisXudong Zhang, Wanyue Zhao, Wenhua Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2022
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/LymphomaMingzhi Zhang, Dan Chen, Xiaorui Fu, et al.
Nature Communications|September 19, 2019
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphomaZhaoming Li, Xudong Zhang, Weili Xue, et al.
JAMA Oncology|June 16, 2022
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical TrialXinhua Wang, Lei Zhang, Xiangli Liu, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Oncotarget|July 8, 2016
Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149Lei Zhang, Sisi Jia, Yangyang Ma, et al.
Immunotherapy|June 26, 2020
A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphomaXinfeng Chen, Xin Li, Yanfen Liu, et al.
Therapeutic Advances in Medical Oncology|March 9, 2026
Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysisXudong Zhang, Wanyue Zhao, Wenhua Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2022
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/LymphomaMingzhi Zhang, Dan Chen, Xiaorui Fu, et al.
Nature Communications|September 19, 2019
Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphomaZhaoming Li, Xudong Zhang, Weili Xue, et al.
JAMA Oncology|June 16, 2022
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical TrialXinhua Wang, Lei Zhang, Xiangli Liu, et al.
Pageof 14